A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus-Reference-Cited by-同舟云学术

A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus

Published:2013 Issue: Volume:2 Page:e114
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Koh Sarene,Shimasaki Noriko,Suwanarusk Rossarin,Ho Zi Zong,Chia Adeline,Banu Nasirah,Wu Howland Shanshan,Ong Alice Soh Meoy,Gehring Adam J,Stauss Hans,Renia Laurent,Sällberg Matti,Campana Dario,Bertoletti Antonio

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference35 articles.

1. Estimating the world cancer burden: Globocan 2000;Parkin;Int J Cancer,2001

2. Epidemiology of viral hepatitis and hepatocellular carcinoma;El-Serag;Gastroenterology,2012

3. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma;Sung;Nat Genet,2012

4. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma;Brechot;Nature,1980

5. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell;Edman;Nature,1980

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy;Biomedicine & Pharmacotherapy;2023-10

2. Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy;Cellular & Molecular Immunology;2023-09-05

3. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial;Hepatology International;2023-04-17

4. G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma;Nature Communications;2023-02-02

5. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood;Immunotherapy Advances;2023-01-01